Alume Biosciences Announces First Patient Dosed with ALM-488 in Phase 3 Pivotal Study in Patients Undergoing Head and Neck Surgery
ALM-488 is a peptide-dye conjugate designed to fluorescently highlight nerves in real time during surgery
Excerpt from the Press Release:
LA JOLLA, Calif., Aug. 23, 2022 /PRNewswire/ — Alume Biosciences, Inc, a leader in the field of nerve-targeted diagnostics and therapeutics, today announced that the first patient has been dosed in a Phase 3 pivotal study of ALM-488 (NCT05377554). ALM-488 is a peptide-dye conjugate designed to highlight nerves with fluorescence in real time during surgery.
“The successful initiation of this Phase 3 pivotal study is another major milestone for Alume. It marks the final phase of clinical trial testing for ALM-488 for patients undergoing Head and Neck Surgery” said Brett Berman, MD, chief medical officer at Alume Biosciences. “This study underscores our commitment to improve intraoperative visualization of nerves, enabling Precision Surgery™“.
Alume successfully completed Phase 1/2 studies of ALM-488 in patients undergoing Head and Neck Surgery in 2021. The Phase 3 studies are being conducted at multiple academic medical centers throughout the US, and they are projected to be completed in 2023.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?